Related Tags >> Surfaxin FDA FDA approvable letter FDA review

Discovery Labs News

Most Popular Discovery Labs Story

FDA rejects Discovery Labs' Surfaxin

April 20, 2009 — 9:48am ET | By Maureen Martino

Shares of Discovery Laboratories plunged today as the FDA announced that it wouldn't approve the company's drug Surfaxin for treatment of respiratory illness in infants. The agency's primary question Read more...

Discovery Labs Press Releases

Discovery Labs Signs Manufacturing Agreement for AFECTAIR®
Discovery Labs Secures $35 Million Committed Equity Financing Facility
Discovery Labs and FDA Establish Path for Potential Surfaxin Approval FDA Supports Proposed BAT Optimization
Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for SURFAXIN Approval
Discovery Labs Announces Resignation of CEO Robert J. Capetola, Ph.D.; W. Thomas Amick, Board Chairman , Appointed Interim CEO

Latest Headlines

Discovery Labs names new CEO
October 15, 2010
Discovery Labs hit with fresh setback on PhII Surfaxin failure
June 9, 2010
Discovery Labs cites progress on Surfaxin response
May 19, 2010
Surfaxin approval will hinge on preclinical work
February 16, 2010
Discovery Labs shares soar on FDA's trial consensus
September 30, 2009
Discovery Labs shares boosted as FDA meeting looms
September 11, 2009
After surfaxin setbacks, Discovery Labs appoints new leader
August 14, 2009
Discovery mulls options as it hunts for cash, partner
July 30, 2009
Discovery Labs: Surfaxin approval unlikely
July 1, 2009
FDA rejects Discovery Labs' Surfaxin
April 20, 2009
Discovery Labs shares dive on FDA delay
June 19, 2008
Discovery secures $60M financing deal
May 27, 2008
Battered Discovery Labs tries to reassure investors
May 5, 2008
FDA delays Discovery Labs approval
May 2, 2008
Discovery Labs to raise $25M
December 7, 2007

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events